Colon Cancer Alliance Appoints InKine CEO, Leonard S. Jacob, M.D., Ph.

    Business Editors/Health/Medical Writers

    BLUE BELL, Pa.--(BUSINESS WIRE)--Jan. 18, 2005--InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that Leonard S. Jacob, M.D., Ph.D. has been appointed to the Colon Cancer Alliance's (CCA) Board of Directors. The CCA is a national, non-profit organization committed to the elimination of suffering caused by cancer of the colon, rectum, cecum, appendix and anus. The CCA also provides free patient support services and facilitates access to information, educates the public about colorectal cancer and encourages early detection through appropriate screening, advocates for research to develop more effective treatments and a cure and advocates for legislation to support public funding for all cancers, particularly colorectal cancer.
    "Our Alliance's important mission and ambitious goals will be well-served by Dr. Jacob's outstanding abilities and dedication to excellence," said Kevin Lewis, the CCA's Chair. "Dr. Jacob's entrepreneurial experience in addition to his leadership will be invaluable to the CCA."
    Dr. Jacob stated, "It is my honor and pleasure to accept the CCA's invitation to join its Board of Directors. The CCA has made tremendous contributions to colon cancer awareness over the last six years. I am committed to the CCA's mission and am eager to assist the CCA in educating the public about colorectal cancer and the advantages of early detection and screening."

    About the Colon Cancer Alliance

    The Colon Cancer Alliance is a national, non-profit organization committed to the elimination of suffering caused by cancer of the colon, rectum, cecum, appendix and anus. The Colon Cancer Alliance provides free patient support services and facilitates access to information, educates the public about colorectal cancer and encourages early detection through appropriate screening, advocates for research to develop more effective treatments and a cure and advocates for legislation to support public funding for all cancers, particularly colorectal cancer. For more information, visit www.ccalliance.org or call 1-877-422-2030.

    About InKine Pharmaceutical

    InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol(R) is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat(R), is an oral hyoscyamine spray for the treatment of a variety of indications. The Company is also promoting VSL#3(R), a probiotic that is effective in treating certain gastrointestinal disorders. Additionally, the Company is developing INKP-102, an advanced generation purgative, which recently completed Phase II clinical trials for bowel cleansing prior to colonoscopy, Visicol(R) for use as a laxative in treating patients with constipation. For further information, please visit InKine on its web site http://www.inkine.com.

    In addition to historical facts or statement of current condition, this press release and other statements made from time to time by representatives of the Company contain or may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.

--30--ML/ny*

CONTACT: InKine Pharmaceutical Company, Inc. Robert Apple, 215-283-6850 or Wolfe Axelrod Weinberger Assoc. LLC Don Weinberger, 212-370-4500 don@wolfeaxelrod.com

KEYWORD: PENNSYLVANIA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: InKine Pharmaceutical Company, Inc.

Copyright Business Wire 2005